# Dose Response Study of Patients With Erythematous Rosacea

> **NCT01186068** · PHASE2 · COMPLETED · sponsor: **Vicept Therapeutics, Inc.** · enrollment: 175 (estimated)

## Conditions studied

- Erythematous (Type One) Rosacea

## Interventions

- **DRUG:** V-101
- **OTHER:** vehicle

## Key facts

- **NCT ID:** NCT01186068
- **Lead sponsor:** Vicept Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2010-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186068, "Dose Response Study of Patients With Erythematous Rosacea". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01186068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*